3-Glucosyl-2,3\',4,4\',6-pentahydroxybenzophenone



Compound IDCDAMM01671
Common name3-Glucosyl-2,3\',4,4\',6-pentahydroxybenzophenone
IUPAC name(3,4-dihydroxyphenyl)-[2,4,6-trihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methanone
Molecular formulaC19H20O11

Experimental data

Retention time0.36
Adduct[2M+NH4]+
Actual mz866.244
Theoretical mz866.236
Error8.86
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.8803

Identifiers and class information

Inchi keyVYGJDASIWDWDAM-UHFFFAOYNA-N
SmilesO=C(C1=CC=C(O)C(O)=C1)C2=C(O)C=C(O)C(=C2O)C3OC(CO)C(O)C(O)C3O
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)5
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)12
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)424.36
Computed dipole moment(dipole)9.406
Total solvent accessible surface area (SASA)608.267
Hydrophobic component of SASA (FOSA)84.126
Hydrophilic component of SASA (FISA)388.631
Pie component of the SASA (PISA)135.51
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1122.92
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)12.25
Free energy of solvation of dipole (dip^2/V)0.0787822
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0532833
Globularity descriptor (glob)0.858954
Predicted polarizability in cubic angstroms (QPpolrz)32.374
Predicted hexadecane/gas partition coefficient (QPlogPC16)13.968
Predicted octanol/gas partition coefficient (QPlogPoct)29.344
Predicted water/gas partition coefficient (QPlogPw)24.419
Predicted octanol/water partition coefficient (QPlogPo/w)-1.611
Predicted aqueous solubility (QPlogS)-1.891
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.59
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.461
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.044
Predicted brain/blood partition coefficient (QPlogBB)-3.671
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.613
Predicted skin permeability, log Kp (QPlogKp)-7.052
PM3 calculated ionization potential (IP(ev))8.945
PM3 calculated electron affinity (EA(eV))0.286
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)-0.891
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)214.313
Number of nitrogen and oxygen atoms (#NandO)11
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
P13866SLC5A1Sodium/glucose cotransporter 1T54771SwissTargetPrediction
P34913EPHX2Epoxide hydrataseT35734SwissTargetPrediction
P43166CA7Carbonic anhydrase VIIT37541SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P11387TOP1DNA topoisomerase IT09826SEA
P32320CDACytidine deaminase (by homology)T79027SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P52789HK2Hexokinase type IIT96685SEA
Q9NY91SLC5A4Low affinity sodium-glucose cotransporterT22583SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P16109SELPP-selectinT10965SwissTargetPrediction
P14151SELLLeukocyte adhesion molecule-1T60526SwissTargetPrediction and SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P17936IGFBP3Insulin-like growth factor binding protein 3T33455SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
P04637TP53Tumour suppressor p53/oncoprotein Mdm2T15739SwissTargetPrediction
P09382LGALS1Galectin-1T09544SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P05231IL6Interleukin-6T32578SEA
P24593IGFBP5Insulin-like growth factor binding protein 5T17008SEA
P24592IGFBP6Insulin-like growth factor binding protein 6T61800SEA
P18065IGFBP2Insulin-like growth factor binding protein 2T64268SEA
P08833IGFBP1Insulin-like growth factor binding protein 1T15048SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T54771DI0120Diabetes mellitus[ICD-11: 5A10]P13866SLC5A1
T54771DI0175Heart failure[ICD-11: BD10-BD1Z]P13866SLC5A1
T54771DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P13866SLC5A1
T35734DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P34913EPHX2
T35734DI0190Hypertension[ICD-11: BA00-BA04]P34913EPHX2
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T09826DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P11387TOP1
T09826DI0095Colorectal cancer[ICD-11: 2B91]P11387TOP1
T09826DI0238Lung cancer[ICD-11: 2C25]P11387TOP1
T09826DI0321Ovarian cancer[ICD-11: 2C73]P11387TOP1
T09826DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P11387TOP1
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T96685DI0133Epidermal dysplasias[ICD-11: EK90]P52789HK2
T22583DI0009Acute diabete complication[ICD-11: 5A2Y]Q9NY91SLC5A4
T22583DI0417Type 2 diabetes mellitus[ICD-11: 5A11]Q9NY91SLC5A4
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T33455DI0115Dementia[ICD-11: 6D80-6D8Z]P17936IGFBP3
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T15739DI0233Lip/oral cavity/pharynx neoplasm[ICD-11: 2B6E]P04637TP53
T15739DI0323Ovarian dysfunction[ICD-11: 5A80]P04637TP53
T15739DI0413Transplant rejection[ICD-11: NE84]P04637TP53
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6

Copyright © 2025